The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
Open accessAbstract
The beneficial actions of nonsteroid anti-inflammatory drugs (NSAID) can be associated with inhibition of cyclo-oxygenase (COX)-2 whereas their harmful side effects are associated with inhibition of COX-1. Here we report data from two related assay systems, the human whole blood assay and a modified human whole blood assay (using human A549 cells as a source of COX-2). This assay we refer to as the William Harvey Modified Assay. Our aim was to make meaningful comparisons of both classical NSAIDs and newer COX-2-selective compounds. These comparisons of the actions of >40 NSAIDs and novel COX-2-selective agents, including celecoxib, rofecoxib and diisopropyl fluorophosphate, demonstrate a distribution of compound selectivities toward COX-1 that aligns with the risk of serious gastrointestinal complications. In conclusion, this full in vitro analysis of COX-1/2 selectivities in human tissues clearly supports the theory that inhibition of COX-1 underlies the gastrointestinal toxicity of NSAIDs in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Self-citationVane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
Self-citationGoodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540120077042 · Cited by 2,371
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Self-citationHawkey, C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12154-2 · Cited by 1,173
Henry, D., Lim, L. L.-Y., Rodriguez, L. A. G., Gutthann, S. P., Carson, J. L., Griffin, M., Savage, R., Logan, R., Moride, Y., Hawkey, C., et al. (1996) · BMJ · doi:10.1136/bmj.312.7046.1563 · Cited by 827
Patrignani, P., Panara, M. R., Greco, A., Fusco, O., Natoli, C., Iacobelli, S., Cipollone, F., Ganci, A., Créminon, C., & Maclouf, J. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24061-7 · Cited by 518
Reuter, B. K., Asfaha, S., Buret, A., Sharkey, K. A., & Wallace, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119013 · Cited by 423
Clinical Pharmacokinetics of Diclofenac: Therapeutic Insights and Pitfalls
Davies, N. M., & Anderson, K. E. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733030-00003 · Cited by 398
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
Whittle, B. J. R., Higgs, G. A., Eakins, K. E., Moncada, S., & Vane, J. R. (1980) · Nature · doi:10.1038/284271a0 · Cited by 392
Self-citationKetorolac: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential
Buckley, M. M.-T., & Brogden, R. N. (1990) · Drugs · doi:10.2165/00003495-199039010-00008 · Cited by 348
García Rodríguez, L. A., Cattaruzzi, C., Troncon, M. G., & Agostinis, L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.33 · Cited by 335
Mitchell, J. A., Belvisi, M. G., Akarasereenont, P., Robbins, R. A., Kwon, O. ‐., Croxtall, J. J., Barnes, P. J., & Vane, J. R. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb17093.x · Cited by 307
Self-citationKinetic basis for selective inhibition of cyclo-oxygenases
Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K., & Isakson, P. C. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3390607 · Cited by 287
Brideau, C., Kargman, S., Liu, S., Dallob, A. L., Ehrich, E. W., Rodger, I. W., & Chan, C. C. (1996) · Inflammation Research · doi:10.1007/bf02265118 · Cited by 279
Dequeker, J., Hawkey, C., Kahan, A., Steinbruck, K., Alegre, C., Baumelou, E., Begaud, B., Isomaki, H., Littlejohn, G., Mau, J., et al. (1998) · Rheumatology · doi:10.1093/rheumatology/37.9.946 · Cited by 227
Noble, S., & Balfour, J. A. (1996) · Drugs · doi:10.2165/00003495-199651030-00007 · Cited by 165
Davis, R., Brogden, R. N., Markham, A., & Faulds, D. (1994) · Drugs · doi:10.1007/bf03257477 · Cited by 160
Mitchell, J. A., Saunders, M., Barnes, P. J., Newton, R., & Belvisi, M. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.907 · Cited by 148
Self-citationClinical Pharmacokinetics of Flurbiprofen and its Enantiomers
Davies, N. M. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00002 · Cited by 141
Young, J. M., Panah, S., Satchawatcharaphong, C., & Cheung, P. S. (1996) · Inflammation Research · doi:10.1007/bf02259611 · Cited by 97
Selective COX‐2 inhibitors and human inflammatory bowel disease
Mccartney, Mitchell, Fairclough, et al. (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00585.x · Cited by 74
Etodolac Clinical Pharmacokinetics
Brocks, D. R., & Jamali, F. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426040-00003 · Cited by 68
HAMILTON, L. C., Mitchell, J. A., Tomlinson, A., & Warner, T. D. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.2.245 · Cited by 55
Self-citationRainsford, K. D. (1989) · Inflammation and drug therapy series · doi:10.1007/978-94-009-1253-3_3 · Cited by 10
Cited by
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Metadata
- Authors
- Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-06-22
- Volume
- 96
- Issue
- 13
- Pages
- 7563-7568
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2038410983
- Cited by
- 1,519
- References
- 25
- FWCI
- 48.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.